

NEXIEN BIOPHARMA

FACT SHEET / MARCH 2019





INVESTMENT HIGHLIGHTS

- Significant greenfield opportunity in the cannabinoid pharmaceutical space
- Experienced management team with proven industry track record
- Advancing novel drug formulations with differentiated therapeutic benefits
- Flagship R&D programs with multiple potential catalysts over the next 1-2 years
- Opportunity to sub-license delivery technology for cannabinoid-based applications

RECENT COMPANY NEWS

- **March 5, 2019** - Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office
- **February 26, 2019** - Nexien BioPharma to File Pre-IND Meeting Request with the FDA
- **November 28, 2018** - Nexien BioPharma and Ivy League University Medical School Collaborate on Pre-Clinical Cannabinoid Studies
- **October 30, 2018** - Nexien BioPharma Acquires Princeton-Based CRx Bio

DRUG DEVELOPMENT PIPELINE

Therapeutic Area	Patent Identifier
 Convulsive Disorders	NXEN01
 Myotonic Dystrophy	NXEN04
Organophosphate / Carbamate Toxicity	NXEN08
Pain Disorders	NXEN03
Chronic Traumatic Encephalopathy	NXEN02

 = Flagship Development Programs

Nexien BioPharma, Inc. (OTCQB: NXEN) is a next generation biopharmaceutical company focused on research, development, and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems. Nexien's R&D programs are advancing cannabinoid formulations in accordance with U.S. Food and Drug Administration pre-clinical and clinical pathways. Nexien's flagship development programs seek to significantly improve the treatment of certain convulsive disorders and myotonic dystrophy. www.nexienbiopharma.com

CANNABINOID PHARMACEUTICALS ESTIMATED U.S. MARKET SIZE BY 2029¹



Nexien's
Focus Area

Medical Marijuana	Rx Cannabinoid Pharmaceuticals
Federally illegal (DEA Sch. 1)	Federally legal
State medical markets gravitate toward adult use markets	Globally scalable
QA/QC issues	Robust QA/QC
Regulatory challenges	FDA regulated

Cannabinoid – A cannabinoid is one of a class of diverse chemical compounds that acts on cannabinoid receptors in cells that alter neurotransmitter release in the brain. Ligands for these receptor proteins include the endocannabinoids (produced naturally in the body by animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids.

¹ Source: Ackrell Capital, LLC


OVERVIEW OF NEXIEN'S FLAGSHIP DEVELOPMENT PROGRAMS

	NXEN01	NXEN04
Indications	<p>Epilepsy: A neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions, associated with abnormal electrical activity in the brain.</p> <p>Refractory epilepsy: Refractory epilepsy occurs when standard of care medicine isn't bringing seizures under control.</p>	<p>Myotonic dystrophy (DM) is part of a group of inherited disorders called muscular dystrophies. It is the most common form of muscular dystrophy that begins in adulthood. Myotonic dystrophy is characterized by progressive muscle wasting and weakness. People with this disorder often have prolonged muscle contractions (myotonia) and are not able to relax certain muscles after use.</p>
Prevalence (estimated)	<ul style="list-style-type: none"> 3.4 million U.S. 50 million worldwide 	<ul style="list-style-type: none"> 39.5 in 100,000 U.S. 1 in 8,000 worldwide
Treatment Market (est.)	<ul style="list-style-type: none"> Epilepsy: \$5.9 billion by 2024 Refractory epilepsy: \$2.5 billion by 2024 	<ul style="list-style-type: none"> Muscular Dystrophy: \$4.1 billion by 2024 (DMD and DM)

Sources: World Health Organization (WHO) "Epilepsy". WHO Factsheet, October 2012: number 999. (2014); The consequences of refractory epilepsy and its treatment. *Epilepsy & Behavior*, 37, 59-70. doi:10.1016/j.yebeh.2014.05.031; Zion Market Research (August 10, 2018); Prevalence of Duchenne and Becker muscular dystrophies in the United States. *Pediatrics*. 2015

ANTICIPATED NEAR-TERM DEVELOPMENT MILESTONES

NXEN01: Convulsive Disorders



NXEN04: Myotonic Dystrophy



Nexien Disclosure Notice: This document may contain "forward-looking statements, which are deemed to be any statements made by or on behalf of Nexien BioPharma that are not statements of historical facts. These statements reflect current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this release, including the factors set forth in "Risk Factors" in our most recent Form 10-K filed with the Securities and Exchange Commission (SEC) and subsequent filings with the SEC. Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. Nexien BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law. The Equity Group Inc. is retained by Nexien to provide investor relations services.

Nexien Contact:

Alex Wasyl, CEO

info@nexienbiopharma.com

IR Contact:

Kalle Ahl, CFA, The Equity Group

kahl@equityny.com, 212-836-9614